Global Pneumococcal Vaccine Market 2023 by Manufacturers, Regions, Type and Application, Forecast to 2029

Pneumococcal Vaccine is a kind of vaccine used to prevent infection caused by pneumococcal bacteria. 
There are two types of Pneumococcal Vaccine: conjugate vaccines and polysaccharide vaccines.
23-Valent Pneumococcal Polysaccharide Vaccine (PPSV 23) is polysaccharide vaccine. Pneumococcal conjugate vaccines contain PCV 7/13 (Pfizer) and PCV10 (GSK).
According to our (Global Info Research) latest study, the global Pneumococcal Vaccine market size was valued at USD 7408.6 million in 2022 and is forecast to a readjusted size of USD 7972.1 million by 2029 with a CAGR of 1.1% during review period. The influence of COVID-19 and the Russia-Ukraine War were considered while estimating market sizes.
At present, only MSD, Sanofipasteur and CDIBP can produce PPSV 23, and they hold key technologies and patents, with high-end customers, have been formed in the monopoly position in the industry. As for PCV 13, only Pfizer can supply it. And GSK is the only one manufacturing PCV 10. However, there are some companies working on research of Pneumococcal Vaccine. Pfizer is the leader of this industry with 84% market shares.
North America is the largest consumption market of Pneumococcal Vaccine with sales market share nearly 40%. The second place is Europe, following North America with sales market share over 18%. Asia-Pacific is another important market of Pneumococcal Vaccine, enjoy nearly 16% sales market share, but the consumption experienced a sharp decrease due to approval of government departments in last few years.
This report is a detailed and comprehensive analysis for global Pneumococcal Vaccine market. Both quantitative and qualitative analyses are presented by manufacturers, by region & country, by Type and by End User. As the market is constantly changing, this report explores the competition, supply and demand trends, as well as key factors that contribute to its changing demands across many markets. Company profiles and product examples of selected competitors, along with market share estimates of some of the selected leaders for the year 2023, are provided.
Key Features:
Global Pneumococcal Vaccine market size and forecasts, in consumption value ($ Million), sales quantity (K Doses), and average selling prices (USD/Dose), 2018-2029
Global Pneumococcal Vaccine market size and forecasts by region and country, in consumption value ($ Million), sales quantity (K Doses), and average selling prices (USD/Dose), 2018-2029
Global Pneumococcal Vaccine market size and forecasts, by Type and by End User, in consumption value ($ Million), sales quantity (K Doses), and average selling prices (USD/Dose), 2018-2029
Global Pneumococcal Vaccine market shares of main players, shipments in revenue ($ Million), sales quantity (K Doses), and ASP (USD/Dose), 2018-2023
The Primary Objectives in This Report Are:
To determine the size of the total market opportunity of global and key countries
To assess the growth potential for Pneumococcal Vaccine
To forecast future growth in each product and end-use market
To assess competitive factors affecting the marketplace
This report profiles key players in the global Pneumococcal Vaccine market based on the following parameters - company overview, production, value, price, gross margin, product portfolio, geographical presence, and key developments. Key companies covered as a part of this study include Pfizer, GSK, MSD, Sanofipasteur and CDIBP. etc.
This report also provides key insights about market drivers, restraints, opportunities, new product launches or approvals, COVID-19 and Russia-Ukraine War Influence.
Market Segmentation
Pneumococcal Vaccine market is split by Type and by End User. For the period 2018-2029, the growth among segments provides accurate calculations and forecasts for consumption value by Type, and by End User in terms of volume and value. This analysis can help you expand your business by targeting qualified niche markets.
Market segment by Type
    PPSV 23
    PCV 7/13
    PCV 10
Market segment by End User
    Child
    Adult
Major players covered
    Pfizer
    GSK
    MSD
    Sanofipasteur
    CDIBP
Market segment by region, regional analysis covers
    North America (United States, Canada and Mexico)
    Europe (Germany, France, United Kingdom, Russia, Italy, and Rest of Europe)
    Asia-Pacific (China, Japan, Korea, India, Southeast Asia, and Australia)
    South America (Brazil, Argentina, Colombia, and Rest of South America)
    Middle East & Africa (Saudi Arabia, UAE, Egypt, South Africa, and Rest of Middle East & Africa)
The content of the study subjects, includes a total of 15 chapters:
Chapter 1, to describe Pneumococcal Vaccine product scope, market overview, market estimation caveats and base year.
Chapter 2, to profile the top manufacturers of Pneumococcal Vaccine, with price, sales, revenue and global market share of Pneumococcal Vaccine from 2018 to 2023.
Chapter 3, the Pneumococcal Vaccine competitive situation, sales quantity, revenue and global market share of top manufacturers are analyzed emphatically by landscape contrast.
Chapter 4, the Pneumococcal Vaccine breakdown data are shown at the regional level, to show the sales quantity, consumption value and growth by regions, from 2018 to 2029.
Chapter 5 and 6, to segment the sales by Type and end user, with sales market share and growth rate by type, end user, from 2018 to 2029.
Chapter 7, 8, 9, 10 and 11, to break the sales data at the country level, with sales quantity, consumption value and market share for key countries in the world, from 2017 to 2022.and Pneumococcal Vaccine market forecast, by regions, type and end user, with sales and revenue, from 2024 to 2029.
Chapter 12, market dynamics, drivers, restraints, trends, Porters Five Forces analysis, and Influence of COVID-19 and Russia-Ukraine War.
Chapter 13, the key raw materials and key suppliers, and industry chain of Pneumococcal Vaccine.
Chapter 14 and 15, to describe Pneumococcal Vaccine sales channel, distributors, customers, research findings and conclusion.